Valter Gattei

Pordenone, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 189 publications

Bendamustine in indolent lymphoma: Letting the dust settle down.

Bendamustine in indolent lymphoma: Letting the dust settle down.

Journal: Cancer

Published: July 07, 2026

The Role of Direct-Acting Antivirals (DAAs) in Hepatitis C Virus-Associated Lymphoproliferative Disorders.

The Role of Direct-Acting Antivirals (DAAs) in Hepatitis C Virus-Associated Lymphoproliferative Disorders.

Journal: Cancers

Published: May 05, 2026

From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL Management.

From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL Management.

Journal: European journal of haematology

Published: March 24, 2026

Dissecting diffuse large B-cell lymphoma heterogeneity: New insights from a state-specific molecular characterisation.

Dissecting diffuse large B-cell lymphoma heterogeneity: New insights from a state-specific molecular characterisation.

Journal: Clinical and translational medicine

Published: March 24, 2026

To Treat or Not to Treat: Navigating Early-Stage CLL in the Era of Targeted Therapy.

To Treat or Not to Treat: Navigating Early-Stage CLL in the Era of Targeted Therapy.

Journal: European journal of haematology

Published: March 22, 2026

First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy Regimens.

First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy Regimens.

Journal: European journal of haematology

Published: March 04, 2026

Correction: Tonon et al. 5-Azacytidine Downregulates the Proliferation and Migration of Hepatocellular Carcinoma Cells In Vitro and In Vivo by Targeting miR-139-5p/ROCK2 Pathway. Cancers 2022, 14, 1630.

Correction: Tonon et al. 5-Azacytidine Downregulates the Proliferation and Migration of Hepatocellular Carcinoma Cells In Vitro and In Vivo by Targeting miR-139-5p/ROCK2 Pathway. Cancers 2022, 14, 1630.

Journal: Cancers

Published: February 27, 2026

Venetoclax in Combination With Chemo-Immunotherapy in Richter Transformation: A Real-Life Experience.

Venetoclax in Combination With Chemo-Immunotherapy in Richter Transformation: A Real-Life Experience.

Journal: Hematological oncology

Published: February 14, 2026

Cryoglobulinemia: An update on classification, pathophysiology, clinical presentation, and management.

Cryoglobulinemia: An update on classification, pathophysiology, clinical presentation, and management.

Journal: Journal of internal medicine

Published: November 26, 2025

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12.

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12.

Journal: Blood advances

Published: October 22, 2025

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Journal: Hematological oncology

Published: October 18, 2025

How many NOTCHes (activation pathways) are there in CLL?

How many NOTCHes (activation pathways) are there in CLL?

Journal: Blood

Published: October 16, 2025

Showing 1-12 of 189

Last Updated: 09/26/2026